Fecal *1-antitripsyn clearance in the differential diagnosis of steatorrhea

Bai, J. C; Sugai, Emilia; Moran, C; Sambuelli, Alicia; Vásquez, H; Mazure, R; Boerr, L; Mackenzie, D.
Acta gastroenterol. latinoam ; 22(2): 95-8, abr.-jun. 1992. ilus, tab
Artículo en Inglés | LILACS | ID: lil-116663

Documentos relacionados

  1. Comparison of the liquid and lyophilized formulations of Prolastin®-C for Alpha<sub>1</sub>-Antitrypsin deficiency: Biochemical characteristics, pharmacokinetics, safety and neoantigenicity in rabbits.
  2. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
  3. Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats.
  4. &#945;<sub>1</sub>-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
  5. Bioequivalence of a Liquid Formulation of Alpha<sub>1</sub>-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha<sub>1</sub>-PI) in Alpha<sub>1</sub>-Antitrypsin Deficiency.
  6. Human plasma-derived alpha<sub>1</sub> -proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: A randomized, placebo-controlled proof-of-concept study.
  7. Development and analysis of alpha 1-antitrypsin neoglycoproteins: the impact of additional N-glycosylation sites on serum half-life.
  8. Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
  9. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy.
  10. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases.